NCM · Financial Statements

Aligos Therapeutics, Inc. (ALGS) Financial Statements

$4.78 NCM: ALGS Market Cap $29.85M

Aligos Therapeutics, Inc. most recently reported annual revenue of $2.0M, a net loss of $24.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Aligos Therapeutics, Inc.: net profit was positive in 0 of 8 reported years; operating margin moved from -2943.8% to -4024.9%, a shift of -1081.1 percentage points; the most recent year shows a net loss of $24.0M.

Income Statement — 8 Years (USD millions)

Metric20182019202020212022202320242025
Revenue$0$0$0$4.0M$14.0M$16.0M$4.0M$2.0M
Operating Expenses$14.0M$54.0M$98.0M$133.0M$111.0M$104.0M$93.0M$90.0M
Operating Profit$-14.0M$-54.0M$-98.0M$-128.0M$-98.0M$-88.0M$-89.0M$-88.0M
Operating Margin0.0%0.0%0.0%-2943.8%-701.7%-567.5%-2259.9%-4024.9%
Other Income$0$2.0M$-11.0M$0$2.0M$1.0M$-42.0M$64.0M
Interest$0$0$11.0M$0$0$0$0$0
Depreciation$1.0M$2.0M$3.0M$4.0M$4.0M$3.0M$3.0M$1.0M
Profit Before Tax$-14.0M$-52.0M$-108.0M$-128.0M$-96.0M$-87.0M$-131.0M$-24.0M
Tax$0$-160,000$-150,000$-110,000$-110,000$-920,000$-250,000$-1.3M
Net Profit$-14.0M$-52.0M$-109.0M$-128.0M$-96.0M$-88.0M$-131.0M$-24.0M
EPS$-0.66$-2.38$-3.18$-3.22$-2.25$-3.52$-20.94$-2.45
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$3.0M$3.0M$1.0M$1.0M$1.0M$1.0M$0$1.0M$1.0M$0$3.0M$28.0M
Operating Expenses$22.0M$29.0M$23.0M$27.0M$21.0M$21.0M$20.0M$20.0M$29.0M$22.0M$30.0M$30.0M
Operating Profit$-19.0M$-26.0M$-22.0M$-26.0M$-20.0M$-21.0M$-19.0M$-19.0M$-28.0M$-22.0M$-27.0M$-2.0M
Operating Margin-588.8%-969.7%-2235.9%-2489.5%-1586.4%-3269.2%-6187.5%-1924.0%-3827.4%-12907.7%-951.5%-6.8%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-18.0M$-28.0M$-35.0M$5.0M$-19.0M$-82.0M$43.0M$-16.0M$-31.0M$-20.0M$-23.0M$1.0M
Tax$-160,000$110,000$-70,000$3.6M$-470,000$-30,000$100,000$-1.2M$-180,000$-150,000$-1.4M$215.1M
Net Profit$-18.0M$-28.0M$-35.0M$5.0M$-19.0M$-82.0M$43.0M$-16.0M$-32.0M$-20.0M$-23.0M$-2.0M
EPS$-0.41$-1.12$-2.24$0.81$-3.07$-13.08$4.95$-1.53$-3.04$-1.91$-2.21$-0.14

Over the 8 years reported for Aligos Therapeutics, Inc., borrowings decreased from $14.0M in 2018 to $5.0M in 2025, cash stood at $18.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 3.95 times.

Balance Sheet — 8 Years (USD millions)

Metric20182019202020212022202320242025
Total Assets$108.0M$147.0M$265.0M$235.0M$147.0M$152.0M$70.0M$89.0M
Current Assets$92.0M$120.0M$250.0M$204.0M$134.0M$141.0M$62.0M$83.0M
Cash$24.0M$70.0M$220.0M$187.0M$81.0M$136.0M$37.0M$18.0M
Inventory$0$0$0$0$0$0$0$0
Receivables$0$0$0$0$0$0$0$0
Fixed Assets$15.0M$16.0M$15.0M$15.0M$13.0M$10.0M$7.0M$5.0M
Capital Work in Progress$0$0$0$0$0$0$0$0
Investments$67.0M$58.0M$23.0M$19.0M$44.0M$0$20.0M$60.0M
Other Assets$0$0$0$0$0$0$0$0
Total Liabilities$121.0M$211.0M$45.0M$51.0M$43.0M$59.0M$99.0M$35.0M
Current Liabilities$7.0M$14.0M$30.0M$39.0M$33.0M$24.0M$22.0M$21.0M
Borrowings$14.0M$14.0M$13.0M$14.0M$13.0M$11.0M$8.0M$5.0M
Other Liabilities$108.0M$197.0M$32.0M$36.0M$30.0M$48.0M$91.0M$30.0M
Equity$0$0$0$0$0$0$0$0
Reserves$-14.0M$-65.0M$220.0M$185.0M$104.0M$92.0M$-29.0M$54.0M

For Aligos Therapeutics, Inc., operating cash flow was positive in 0 of 8 reported years; free cash flow in the latest year was negative at $83.0M; free cash flow was positive in 0 of 8 years.

Cash Flow Statement — 8 Years (USD millions)

Metric20182019202020212022202320242025
Operating Cash Flow$-6.0M$-47.0M$-74.0M$-116.0M$-79.0M$-79.0M$-81.0M$-83.0M
Investing Cash Flow$-145.0M$4.0M$31.0M$2.0M$-27.0M$45.0M$-18.0M$-38.0M
Financing Cash Flow$0$1.0M$-3.0M$0$0$71.0M$0$0
Net Cash Flow$25.0M$46.0M$151.0M$-34.0M$-106.0M$54.0M$-99.0M$-19.0M
Free Cash Flow$-9.0M$-50.0M$-76.0M$-117.0M$-80.0M$-79.0M$-81.0M$-83.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.10
FCF Yield-275.72%
Quick Ratio2.19
Interest Coverage—
Return 1Y-31.65%
Return 3Y-77.44%
Return 5Y-98.50%

Aligos Therapeutics, Inc. (ALGS) financials — frequently asked questions

What is Aligos Therapeutics, Inc.'s annual revenue?

Aligos Therapeutics, Inc. (ALGS) reported annual revenue of $2.0M in its most recent fiscal year.

What is Aligos Therapeutics, Inc.'s net profit?

Aligos Therapeutics, Inc. (ALGS) reported a net loss of $24.0M in its most recent fiscal year.

What is ALGS EV/EBITDA?

Aligos Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -0.10. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
ALGS Overview ALGS Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.